Quick Answer
Cadrenal Therapeutics, Inc. reported Stockholders Equity of $2.74 million for fiscal year 2025.
Cadrenal Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $2.74M | -63.2% |
| 2024 | $7.44M | -3.3% |
| 2023 | $7.69M | +238.6% |
| 2022 | -$5.55M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.73M | -19.9% | -36.4% |
| June 30, 2025 | $4.30M | +7.7% | -29.7% |
| March 31, 2025 | $6.11M | -1.3% | -17.8% |
| December 31, 2024 | $7.44M | -3.3% | +118.0% |
| September 30, 2024 | $3.41M | -61.0% | -14.5% |
| June 30, 2024 | $3.99M | +25.7% | -35.5% |
| March 31, 2024 | $6.19M | +52.3% | -19.5% |
| December 31, 2023 | $7.69M | +238.6% | -12.0% |
- Cadrenal Therapeutics, Inc. showed a decrease of -63.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Cadrenal Therapeutics, Inc.’s stockholders equity has grown by 149.3% (from -$5.55 million to $2.74 million).
- The most recent figure is from Cadrenal Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: